DOCMF (Dr. Martens) Change In Receivables: $-12 Mil (TTM As of Mar. 2026)


DOCMF Dr. Martens PLC DOCMF
55 GF Score
Price $0.97
GF Value $0.99
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Dr. Martens Change In Receivables?

Dr. Martens DOCMF 55 Change In Receivables is $-12 Mil as of Mar. 2026. GuruFocus rates DOCMF with a GF Score™ of 55/100 and a GF Value™ of $0.99 (Fairly Valued). The stock has 3 warning signs investors should review.

Dr. Martens's change in receivables for the quarter that ended in Mar. 2026 was $32 Mil. It means Dr. Martens's Accounts Receivable declined by $32 Mil from Sep. 2025 to Mar. 2026 .

Dr. Martens's change in receivables for the fiscal year that ended in Mar. 2026 was $-12 Mil. It means Dr. Martens's Accounts Receivable increased by $12 Mil from Mar. 2025 to Mar. 2026 .

Dr. Martens's Accounts Receivable for the quarter that ended in Mar. 2026 was $75 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Dr. Martens's Days Sales Outstanding for the six months ended in Mar. 2026 was 23.08.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Dr. Martens's liquidation value for the six months ended in Mar. 2026 was $-284 Mil.

Dr. Martens  (OTCPK:DOCMF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Dr. Martens's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=74.667/590.533*91
=23.08

2. In Ben Graham's calculation of liquidation value, Dr. Martens's accounts receivable are only considered to be worth 75% of book value:

Dr. Martens's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=240.4-687.733+0.75 * 74.667+0.5 * 214.4
=-284

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr. Martens Change In Receivables Related Terms

Dr. Martens Change In Receivables Historical Data

* Premium members only.

The historical data trend for Dr. Martens's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr. Martens Change In Receivables Chart

Dr. Martens Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Change In Receivables
Get a 7-Day Free Trial Premium Member Only -30.70 -8.01 29.23 8.14 -11.73

Dr. Martens Semi-Annual Data
Mar18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.44 -29.23 36.69 -44.19 31.87
DOCMF
55GF Score
Dr. Martens PLC DOCMF
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr. Martens Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-12 Mil mean?
Dr. Martens (DOCMF) has a Change In Receivables of $-12 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Dr. Martens and its competitors.
Is Dr. Martens' Change In Receivables too high?
Dr. Martens' current Change In Receivables is $-12 Mil. Overall, Dr. Martens has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr. Martens' Change In Receivables compare to NKE and DECK?
Dr. Martens' Change In Receivables of $-12 Mil can be compared against companies in the Manufacturing - Apparel & Accessories industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Manufacturing - Apparel & Accessories company?
A good Change In Receivables depends on the Manufacturing - Apparel & Accessories industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Dr. Martens and its competitors. Dr. Martens's current Change In Receivables is $-12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Martens stock overvalued right now?
Based on GuruFocus' analysis, Dr. Martens (DOCMF) is currently considered Fairly Valued. The stock's GF Value™ is $0.99, compared to a current price of $0.97 — trading 2% below its estimated fair value. The current Change In Receivables is $-12 Mil. Dr. Martens' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Dr. Martens (DOCMF), the current Change In Receivables is $-12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr. Martens (DOCMF) Overvalued in 2026?

Based on GuruFocus' analysis, Dr. Martens stock appears to be undervalued. The current stock price of $0.97 is trading 2% below its estimated GF Value™ of $0.99. GuruFocus considers Dr. Martens to be Fairly Valued.

Key valuation signals for DOCMF:

  • Change In Receivables: $-12 Mil
  • GF Value™: $0.99 vs. price of $0.97 (2% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the DOCMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr. Martens Business Description

Address 28 Jamestown Road, Camden, London, GBR, NW1 7BY
Dr. Martens PLC is engaged in the footwear business. Its product segments include Originals, Fusion, Kids and Casual, and a complementary range of Accessories. The company has sales through E-commerce, Retail, and Wholesale of Products. Geographically, it derives the majority of its revenue from EMEA and has a presence in the Americas and APAC.
55GF Score

Get the complete analysis for DOCMF

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.97
Price
$0.99
GF Value